Want to join the conversation?
$LLY 3Q15 total OpEx declined by 7% or over $200MM YoverY. R&D expense declined 10%, driven by 2014 charge associated with the termination of tabalumab development and favorable FX rate impact. By geography, US pharma revenue was up 13%, driven by volume, partially offset by price.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?